14 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Showing 14 of 14 clinical reviews.
A clinician-reviewed guide to how Saxenda (liraglutide 3 mg) affects growth, bone density, puberty, and long-term development in adolescents aged 12-17, with trial data, dosing guidance, and safety monitoring protocols.
A complete caregiver guide to administering Saxenda (liraglutide 3 mg) to adolescents ages 12 to 17, covering dose escalation, injection technique, storage, side-effect management, and FDA-approved safety data.
A clinician-reviewed guide to using Saxenda (liraglutide 3 mg) safely in adults aged 65 and older, covering exercise adaptations, fall risk, sarcopenia, hypoglycemia caution, and practical daily activity planning.
A clinician-reviewed guide to liraglutide 3 mg in adolescents aged 12 to 17, covering FDA-approved indications, off-label applications, dosing, efficacy data, and safety considerations.
A physician-reviewed guide on starting, adjusting, and transitioning older adults (65+) from pediatric or young-adult obesity care to liraglutide 3 mg (Saxenda) therapy, with dosing tables, safety data, and evidence-based monitoring protocols.
A comprehensive clinical review of Saxenda (liraglutide 3 mg) use in geriatric patients aged 65+, covering efficacy, safety, muscle and bone considerations, dosing, and monitoring guidance backed by primary-source evidence.
Evidence-based guidance on managing Saxenda (liraglutide 3 mg) in pediatric patients under 12, covering school accommodations, physical activity, nausea timing, hypoglycemia protocols, and communication with teachers and coaches.
Saxenda is not FDA-approved for children under 12, and its pediatric label applies only to ages 12 and older. This guide covers what clinicians and families need to know about transitioning adolescent patients to adult obesity care when they turn 18, including protocol, monitoring, and next steps.
A clinical review of off-label Saxenda (liraglutide 3 mg) use in children under age 12, covering the regulatory status, available trial data, dosing considerations, and safety signals that clinicians and families should understand.
How to manage the transition from adolescent to adult obesity care for patients using Saxenda (liraglutide 3 mg), including timing, dose continuity, provider handoff, and what the evidence says about long-term outcomes.
A clinician-reviewed guide covering how Saxenda (liraglutide 3 mg) affects school performance, physical activity, lunch routines, sports participation, and daily scheduling for adolescents aged 12 to 17.
Saxenda (liraglutide 3 mg) is not FDA-approved for children under 12. This guide explains the current evidence, regulatory status, off-label considerations, and safe injection technique so caregivers can have informed conversations with their child's prescribing physician.
Complete clinical guide for caregivers administering Saxenda (liraglutide 3 mg) to adults aged 65 and older: injection technique, dose escalation, safety monitoring, and geriatric-specific considerations backed by primary-source evidence.
A clinical review of liraglutide 3 mg (Saxenda) use in children under 12, covering FDA approval status, developmental safety data, growth effects, neurodevelopmental considerations, and what current guidelines recommend.